Adjuvant oral Razoxane (ICRF 159) in resectable colo-rectal cancer.

Slevin, M L

Adjuvant oral Razoxane (ICRF 159) in resectable colo-rectal cancer. [electronic resource] - Cancer chemotherapy and pharmacology 1983 - 228-9 p. digital

Publication Type: Clinical Trial; Letter; Research Support, Non-U.S. Gov't

0344-5704

10.1007/BF00255772 doi


Clinical Trials as Topic
Colonic Neoplasms--drug therapy
Humans
Piperazines--administration & dosage
Razoxane--administration & dosage
Rectal Neoplasms--drug therapy